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Background: Recent studies suggest that the chemotactic G-protein-coupled-receptor (GPCR) formyl-peptide-
receptor-like-1 (FPRL1) and the receptor-for-advanced-glycation-end-products (RAGE) play an important role in the
inflammatory response involved in neurodegenerative disorders such as Alzheimer’s disease (AD).
Therefore, the expression and co-localisation of mouse formyl peptide receptor (mFPR) 1 and 2 as well as RAGE in
an APP/PS1 transgenic mouse model using immunofluorescence and real-time RT-PCR were analysed. The
involvement of rat or human FPR1/FPRL1 (corresponds to mFPR1/2) and RAGE in amyloid-β 1–42 (Aβ1-42)-induced
signalling were investigated by extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation. Furthermore, the
cAMP level in primary rat glial cells (microglia and astrocytes) and transfected HEK 293 cells was measured. Formyl
peptide receptors and RAGE were inhibited by a small synthetic antagonist WRW4 and an inactive receptor variant
delta-RAGE, lacking the intracytoplasmatic domains.
Results: We demonstrated a strong increase of mFPR1/2 and RAGE expression in the cortex and hippocampus of
APP/PS1 transgenic mice co-localised to the glial cells. In addition, the Aβ1-42-induced signal transduction is
dependant on FPRL1, but also on FPR1. For the first time, we have shown a functional interaction between
FPRL1/FPR1 and RAGE in RAGE ligands S100B- or AGE-mediated signalling by ERK1/2 phosphorylation and cAMP
level measurement. In addition a possible physical interaction between FPRL1 as well as FPR1 and RAGE was shown
with co-immunoprecipitation and fluorescence microscopy.
Conclusions: The results suggest that both formyl peptide receptors play an essential role in Aβ1-42-induced signal
transduction in glial cells. The interaction with RAGE could explain the broad ligand spectrum of formyl peptide
receptors and their important role for inflammation and the host defence against infections.
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Alzheimer’s disease (AD) is a neurodegenerative disorder
characterised by senile plaques and neurofibrillary tan-
gles. An important component of the plaques in the hu-
man brain is amyloid-β 1–42 (Aβ1-42), a 42 amino acid
peptide fragment derived from sequential proteolytic
cleavage of the amyloid precursor protein by beta- and
gamma-secretases [1]. Aβ1-42 plays a central role in me-
diating neurotoxicity and activates glial cells (astrocytes
as well as microglia). Elevated levels of non-fibrillar [2,3]
and fibrillar Aβ1–42 [4,5] lead to the release of proin-
flammatory cytokines by activated glial cells. This may
subsequently lead to gliosis and cytotoxicity in neurons
[6-8]. However, the role of glial cells in the formation of
amyloid plaques in Alzheimer’s disease remains unknown
[9,10]. The underlying pathogenic mechanisms are not
well understood, especially regarding the initial steps of
cellular Aβ1-42 uptake and the induction of signal trans-
duction and the consequence for the development of the
disease. Recent studies suggest that the chemotactic G-
protein-coupled receptor, formyl-peptide-receptor-like 1
(FPRL1), is involved in Aβ1-42 and PrP106-126-induced
activation and the internalisation in glial cells [11-13].
Furthermore it is indicated that the FPRL1 is expressed
on astrocytes and microglia and plays an essential role in
the inflammatory response [14].
However, it should be noted that a variety of further
receptors were discussed to participate in Aβ1-42-
induced glial cell activation and internalisation. In fact,
previous results suggest an involvement of the scavenger
receptor MARCO (macrophage receptor with collage-
nous structure)[15,16] and the receptor for advanced
glycation endproducts (RAGE)[17]. MARCO is a mem-
brane glycoprotein that can bind to chemically modified
low-density lipoproteins or Gram-positive and Gram
negative bacteria [18,19]. For MARCO, our recent work
shows no involvement in Aβ1-42-induced glial cell acti-
vation [11]. However, we are able to show a physical and
functional interaction between FPRL1 and MARCO in
MARCO ligand fucoidan-induced signaling and in the
host defense against brain infections [11,14]. RAGE is a
multiligand receptor belonging to the immunoglobulin
superfamily [20].
In this study we analysed the expression of formyl
peptide receptors and RAGE and their glial localisation
using fluorescence microscopy and real-time RT-PCR in
an APP/PS1 transgenic mouse model. The murine FPR
gene family has at least six members in contrast to only
three in humans. Fpr1 encodes for the murine FPR1
(mFPR1), which is considered to be the murine ortholo-
gue of human FPR1, whereas Fpr-rs2 (mFPR2) encodes
for receptors that are similar to the human formyl pep-
tide receptor like 1 (FPRL1) [21]. Furthermore, we ex-
amined the involvement of FPRL1, FPR1 and RAGE inAβ1–42-induced signalling by measured the extracellular-
signal regulated kinase 1/2 (ERK 1/2) phosphorylation
and cAMP levels in rat glial and transfected HEK293 cells.
Also, the involvements of the RAGE receptor ligands
S100B as well as AGE-induced signalling were examined.
In addition, a functional and physical interaction between
FPR1, FPRL1 and RAGE using co-immunoprecipitation
and ERK1/2 phosphorylation and cAMP level measure-
ment in rat glial and transfected HEK293 cells was de-
termined. Furthermore, we analysed and quantified the
co-localisation between different receptors and S100B or
Aβ1–42 in transfected HEK293 cells using fluorescence
microscopy. The results suggest that FPRL1 as well as
FPR1 play an essential role in Aβ1–42-induced signal
transduction in glial cells, and also show the capability of
formyl peptide receptors to expand its ligand spectrum
by interacting with the RAGE receptor.
Methods
Reagents
Human Aβ1–42 and formyl-peptide-receptor antagonist
WRW4 [22] were purchased from Dr. P. Henklein (Charité,
Berlin, Germany). Peptides were dissolved at 1 and 10 mM
concentration in dimethylsulfoxide (DMSO), and Aβ1–42 is
present in the soluble form. DMSO used as vehicle in a
concentration of 0.1% showed no significant effects in the
experiments. The RAGE agonists Advanced Glycation
Endproduct-Bovine Serum Albumine (AGE-BSA) and S100
calcium binding protein B (S100B) were purchased from
BioCat (Heidelberg, Germany) and Merck (Darmstadt,
Germany). Forskolin and formyl-methionyl-leucyl-proline
(fMLF) were obtained from Sigma-Aldrich, Munich,
Germany.
APP/PS1 transgenic mouse model
The APP/PS1 transgenic mouse model used in this study
(APPswe/PS1dE9-Line 85) co-expresses a chimeric mouse/
human amyloid precursor protein (APP) 695 harboring
the Swedish K670M/N671L mutations (Mo/HuAPPswe)
and human presenilin 1 (PS1) with the exon-9 deletion
mutation (PS1dE9) under control of the mouse prion
protein promoter [23]. The mouse line was obtained
from Jackson Laboratory (B6.Cg-Tg(APPswe,PSEN1dE9)
85Dbo/J; Stock-Number: 005864; Promoter: Prnp, prion
protein; created by David Borchelt 2006, University of
California, referring to Jackson Laboratory). Wildtype lit-
termates were used as controls. Mice were used at
12 months of age. Mice were fed standard lab chow and
water ad libitum and kept under a 12 h light/dark cycle.
Cloning of cDNA and plasmids
The pcDNA3.1-hFPRL1 plasmid containing a neomycin
resistance gene was kindly provided by Dr. U. Rescher
(Münster, Germany). The pcDNA3.1-hFPR1 containing
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Resource Center (Rolla, Missouri, USA). The pcDNA3.1-
hRAGE and–hRAGEΔcyto plasmids, containing a neomy-
cin resistance gene,were kindly providedbyProf. R.Donato
(Perugia, Italy). RAGEΔcyto (ΔRAGE) is a RAGE mutant
lacking the cytoplasmic domain [24]. The inserts were
subcloned into a pcDNA3.1 expression vector containing a
Zeocin™ resistance gene (Invitrogen, Karlsruhe, Germany).
Cell culture
HEK293 cells (American Type Culture Collection,
Rockville, MD, USA) were subcultivated in Dulbecco’s
modified Eagle’s medium (DMEM; PAA Laboratories,
Pasching, Austria) supplemented with 10% fetal calf serum
(FCS) and 1% penicillin/streptomycin (Carl Roth, Karlsruhe,
Germany). The transfection and selection of HEK293 cells
expressing hFPRL1 was described previously [11]. Using
Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany)
according to the manufacturer’s protocol, HEK293 cells
(American Type Culture Collection, Rockville, MD, USA)
were first transfected with either pcDNA3.1-hFPR1 or –
hFPRL1 plasmid. Stable transfectants were selected in the
presence of 500 μg/ml G418 (Carl Roth, Karlsruhe,
Germany). To generate hFPR1/hFPRL1 cell lines co-
expressing hRAGE or hRAGEΔcyto, cells were subjected to
a second round of transfection with pcDNA3.1-hRAGE or
-hRAGEΔcyto and selected in the presence of 100 μg/ml
Zeocin™ (Invitrogen, Karlsruhe, Germany).
Isolated cerebral cortices and rostral mesencephali
from wistar rats (P2) were stripped of the meninges,
minced and dissociated enzymatically with trypsin from
bovine pancreas (Sigma-Aldrich, Taufkirchen, Germany)
in phosphate-buffered saline and 50 μg/ml DNase I
(Roche Molecular Biochemicals, Mannheim, Germany)
for 30 min at 37°C and crushed mechanically with
Pasteur pipettes. Astrocytes were prepared according
to the protocol of McCarthy and DeVellis [25], which
allows the preparation of nearly pure cultures of astro-
cytes (> 97%) and cultivated in Dulbecco’s modified
Eagle’s medium (DMEM; PAA Laboratories, Pasching,
Austria) supplemented with 10% FCS. Suspended
microglial cells were plated in 75 cm2 cell culture
flasks (Sarstedt, Nümbrecht, Germany) in microglial
cell growth medium and harvested as described previ-
ously [13]. The microglial cell growth medium (DMEM)
containing 10% FCS (heat inactivating from 44-53°C)
and antibiotics (penicillin and streptomycin). After
about ten days, the cells begin to move away from the
cell layer and swim in the supernatant. The cells are col-
lected and then seeded in normal medium (DMEM, 10%
FCS heat inactivated at 56°C, penicillin and strepto-
mycin). Prior to replating microglial cells for different
assays, cell number and viability were estimated by try-
pan blue exclusion. This procedure increased thepurity of the microglial preparation to > 98% with only
very few remaining astrocytes.
RNA isolation and real time RT-PCR
Total RNA was isolated using the peqGold Trifast re-
agent (Peqlab, Erlangen, Germany) according to the
manufacturer’s instructions. RNA samples were reverse-
transcribed by moloney murine leukemia virus (MMLV)
reverse transcriptase (Fermentas, Burlington, Canada) and
random hexamer primers (Invitrogen, Darmstadt,
Germany). The cDNA products were used immediately
for SYBR green (Applied Biosystems, Darmstadt,
Germany) real-time RT-PCR for mus(m)FPR1, mFPR2
and RAGE. Gene expression was monitored using the
StepOne Plus apparatus (Applied Biosystems, Darmstadt,
Germany) according to manufacturer’s protocol [26].
Relative quantification was performed using the ΔCt
method which results in ratios between target genes and
a housekeeping reference gene (18 s). cDNA was ampli-
fied using gene-specific primers described in Table 1.
The specificity of the amplification reaction was deter-
mined by a melting curve analysis. We performed relative
quantification of the signals normalising to the Geomean
of the gene signal from m18s, ribosomal protein L13a
(RPL13a) and TATAbox binding protein (TBP; all primers
Eurofins MWG Operon, Ebersberg, Germany, for primer
sequences please see Table 1) for SYBR Green real time
RT-PCR.
Western blotting
For Western blot analysis of MAP kinase phosphoryl-
ation, rat glial or HEK293 cells were seeded in DMEM
containing 10% FCS. Cells were harvested in a lysis buffer
(50 mM Tris pH 7.5, 100 mM NaCl, 5 mM EDTA, 1%
Triton, 2 mM sodium orthovanadate, 2.5 mM sodium
pyrophosphate, 1 mM glycerol 2-phosphate, 1 mM phe-
nylmethylsulfonylfluoride). Proteins (5 μg for pERK and
ERK2) were resolved in SDS sample buffer, and a Western
blotting procedure was performed as previously de-
scribed in detail [12]. Membranes were incubated with
polyclonal primary antibodies against pERK1/2 (1:500;
sc-7383; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
overnight at 4°C and subsequent detection was performed
with peroxidase-labeled secondary antibodies (Sigma-
Aldrich, Munich, Germany). Antibody binding was de-
tected by enhanced chemiluminescence (Amersham
Pharmacia Biotech, Essex, UK). The membranes were
then stripped and re-probed with anti-ERK2 (1:500; sc-
1647; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
antibody as a loading control. The Western blot bands
were densitometrically evaluated with the program Quan-
tity One (Bio-Rad, Munich, Germany), the pERK-bands
were adjusted with their respective ERK-bands and sub-
sequently, the values were referred to control (=100%).
Table 1 Primer sequences for real-time RT-PCR gene analysis
primer sequence annealing Tm [°C]
mFPR1 for 5’-CACAATCCAAGTCCGTGAACG-3’ 57
rev 5’-CAGCTGTTGAAGAAAGCCAAGG-3’
mFPR2 for 5’-CTGAATGGATCAGAAGTGGTGG-3’ 56
rev 5’-CCCAAATCACTAGTCCATTGCC-3’
mRAGE for 5’-TGACCGCAGTGTAAAGAGTCCC-3’ 59
rev 5’-CCCTTAGCTGGCACTTAGATGG-3’
m18s for 5’-GAATAATGGAATAGGACCGCGG-3’ 57
rev 5’-AAGAATTTCACCTCTAGCGGCG-3’
mTBP for 5’-AGAACAATCCAGACTAGCAGCA-3’ 58
rev 5’-GGGAACTTCACATCACAGCTC-3’
mRPL13a for 5’-GAATAATGGAATAGGACCGCGG-3’ 60
rev 5’-GGCTCGGAATTGGTAGGGG-3’
Slowik et al. Molecular Neurodegeneration 2012, 7:55 Page 4 of 18
http://www.molecularneurodegeneration.com/content/7/1/55Co-immunoprecipitation
Co-immunoprecipitation was performed as previously
described in detail in Brandenburg et al. 2010 [10]. Cells
(1.5 x 106/plates for astrocytes and transfected HEK293
cells, 10 x 106/plates for microglia) were plated onto
100 mm dishes and grown to 80% confluence. Cells were
washed twice with phosphate-buffered saline and har-
vested into ice-cold lysis buffer (10 mM Tris–HCl, pH
7.6, 5 mM EDTA, 3 mM EGTA, 250 mM sucrose, 10 μM
iodoacetamide, and a mixture of proteinase inhibitors:
0.2 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupep-
tin, 1 μg/ml pepstatin A, 1 μg/ml aprotinin, and 10 μg/ml
bacitracin). Subsequently, the cell suspensions were in-
cubated for 30 min on ice and homogenised. The homo-
genates were then centrifuged at 500 g for 5 min at 4°C
to remove not disrupted cells and nuclei. Membranes
were pelleted at 20.000 g for 30 min at 4°C, and pellets
were lysed in detergent buffer (20 mM HEPES, pH 7.4,
150 mM NaCl, 5 mM EDTA, 3 mM EGTA, 4 mg/ml β-
dodecylmaltoside, and the proteinase inhibitors listed
above) for 1 h on ice. Lysates were centrifuged at 20.000 g
for 30 min at 4°C, and the protein content of the result-
ing supernatant was determined using a BCA protein
assay (Pierce, Rockford, IL, USA). Receptor proteins were
immunoprecipitated with 50 μl protein G agarose beads
preloaded with 5 μg anti-FPR1 or anti-FPRL1 antibodies
(for rat glial cells from Santa Cruz; for HEK cells trans-
fected with hFPR1 or hFPRL1, from MBL, Woburn, MA,
USA or Abcam (FPRL1, ab13177)) overnight at 4°C. Beads
were washed five times with detergent buffer and eluted
into 200 μl of SDS-sample buffer (62.5 mM Tris–HCl,
pH 6.8, 2% SDS, 20% glycerol, 100 mM DL-dithiotreitol,
and 0.005% bromphenol blue) at 60°C for 20 min. After
SDS–polyacrylamide gel electrophoresis and electroblot-
ting, membranes were incubated with rabbit anti-FPR1,
FPRL1, RAGE (Abcam, Cambridge, UK; ab3611) anti-
bodies overnight at 4°C. Immunoreactive bands werevisualized using the enhanced chemiluminescence detec-
tion system mentioned above.
Determination of receptor activity by measuring cyclic
AMP accumulation
5 x 104 astrocytes/well, or 7.5 x 104 microglia/well or
1.5 x 104 transfected HEK cells were seeded in a 96 well
culture plate with DMEM containing 10% FCS and incu-
bated for 48 h. The medium was removed and replaced
with 100 μl of serum-free Opti-MEM medium containing
10 μM forskolin (for astrocytes, Sigma) or 25 μM forskolin
(for microglial or HEK cells) plus agonist. Different
forskolin concentrations were used because there is a
difference in cell sensitivities to forskolin-stimulated ad-
enylate cyclase activity. For the formyl peptide receptors
antagonist WRW4, glial cells were pre-incubated in Opti-
MEM medium containing 10 μMWRW4 for 30 min. The
cells were incubated at 37°C for 15 min, and the reaction
was terminated by the removal of the culture medium
and addition of 70 μl lysis buffer (for HEK cells) or
100 μl lysis buffer (for glial cells) followed by 10 min in-
cubation at room temperature. cAMP content was de-
termined using a commercial available colorimetric kit
(Millipore, Schwalbach, Germany).
Fluorescence microscopy
Formalin-fixed and paraffin-embedded 5 μm whole cor-
onary brain sections were examined. For immunofluor-
escence staining, sections were deparaffinized, pretreated
for 3 x 7 min with microwaving in citric acid buffer, per-
meabilized with 0.1% Triton X in PBS for 10 min at
room temperature and after blocking with 1.5% bovine
serum albumine (BSA; Sigma-Aldrich, Taufkirchen,
Germany) in TRIS incubated with either polyclonal
rabbit anti-mFPR1 (1:100; ab101701; Abcam, Cambridge,
UK), anti-mFPR2 (1:100; sc-18191; Santa Cruz Biotech-
nology), anti-RAGE (1:100; ab3611; Abcam, Cambridge,
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Abcam, Cambridge, UK) or polyclonal goat anti-Iba1
(1:100; ab5076; Abcam, Cambridge, UK) overnight at
4°C. Finally, the slices were incubated with donkey anti-
rabbit AlexaFluor 488 (Molecular Probes, Darmstadt,
Germany) and goat anti mouse Cy3 (Sigma-Aldrich,
Taufkirchen, Germany) or rabbit anti-goat AlexaFluor
555 (all 1:250; Molecular Probes, Darmstadt, Germany)
for 1 h at room temperature.Fluorescence staining of primary and cell cultures
Glial or HEK293 cells were grown on glass coverslips. Cov-
erslips were previously coated with poly-L-lysine according
the instruction (Sigma-Aldrich, Munich, Germany). Trans-
fected HEK293 cells were exposed to RAGE agonist S100B
(5 μg/ml = 2.4 μM) for 2 h at 37°C. After fixation with 4%
paraformaldehyde and 0.2% picric acid in a phosphate
buffer at pH 6.9 [11] for 30 min and permeabilisation
with 0.1% TritonX in PBS, cells were blocked in 0.1 M
Tris–HCl pH 7.5 containing 1.5% BSA for 10 min. Cover-
slips were incubated at 4°C overnight with primary anti-
bodies for FPR, FPRL1 or RAGE (for rat glial cells: FPR/
FPRL1 from Santa Cruz; RAGE from AbD Serotec, Düssel-
dorf, Germany (goat) or Abcam (rabbit); for transfected
HEK cells: hFPR1 from MBL (rabbit) or Santa Cruz (goat);
hFPRL1 from Abcam (rabbit) or Everest Biotech, Oxford-
shire, UK (goat); RAGE from AbD Serotec and S100B
from Abcam (ab868, rabbit); Aβ1–42 from Santa Cruz
(sc-58495, mouse) and diluted in TRIS containing 1.5%
BSA. Finally, the coverslips were incubated with donkey
anti-rabbit or anti-goat AlexaFluor 488 (Molecular
Probes, Darmstadt, Germany) and goat anti rabbit Cy3
(Millipore) or rabbit anti-goat AlexaFluor 555 (all 1:250;
Molecular Probes, Darmstadt, Germany) for 1 h at room
temperature. Nuclear staining was performed with bis-
benzimide (Sigma-Aldrich, Taufkirchen, Germany). Cells
were digitally photographed using a LSM7 DUO laser
confocal microscope (Zeiss, Göttingen, Germany).Determination of co-localisation
The Pearson coefficient is a measure of the strength of lin-
ear relationship between two signals. Instead, Spearman
coefficient is a measure of how well any monomeric func-
tion between the variables can describe the relationship.
The Pearson-Spearman correlation (PSC) co-localisation
plugin for ImageJ was used to calculate co-localisation
between target receptors RAGE, FPR1 or FPRL1 and
S100B or Aβ1-42 [27,28]. A subselection as a region of
interest (ROI) was set up around the plasma membrane
using the Selection Brush with a width of 25 pixels. The
value for the background intensity noise threshold was
set up to 40 to calculate the coefficients.Statistical analysis
All in vitro experiments were performed at least in trip-
licate and the values are expressed as mean ± SEM. For
statistical comparison, ANOVA test was used followed
by Bonferroni’s correction. A value of p < 0.05 was con-
sidered statistically significant. The GraphPad Prism 5.0
software was used for statistical calculation (Graph Pad
Software, San Diego, CA, USA).
Results
Increased formyl peptide receptors and RAGE expression
in glial cells in an APP/PS1 transgenic mouse model
In a first set of experiments we investigated the expres-
sion and localisation of the mouse formyl peptide recep-
tors mFPR1 and mFPR2 as well as RAGE in an APP/PS1
transgenic mouse model of AD. We used double fluores-
cence microscopy with receptor and glial cell (GFAP for
activated astrocytes and Iba-1 for microglia/macrophages)
specific antibodies to localise the receptor expression in
mouse brain sections. The receptor expression was ana-
lysed in the cortex and hippocampus of twelve month
old double transgenic mice co-expressing human PS1dE9
andmouse/human (mo/hu) chimeric APP695 (humanized
Aβ domain) harboring the Swedish (K594M/N595L) mu-
tation [23] and compared with wildtype littermates. As
shown in figure 1 and 2, only few GFAP- and Iba-1-
immunoreactive cells and very little mFPR1 (Figures 1A
and 2A), mFPR2 (Figures 1B and 2B) as well as RAGE
(Figures 1C and 2C) immunoreactivity were detected in
the wildtype cortex and hippocampus. In contrast, the
brain slices of contemporary APP/PS1 transgenic mice
showed a strong increase of both GFAP and Iba-1 immu-
noreactivity in the cortex and hippocampus. For mFPR1,
in the cortex the GFAP positive cells showed a slight and
in the hippocampus a clear increase of mFPR1 immuno-
fluorescence (Figure 1A). A significant mFPR1 expression
in brain slices of cortex and hippocampus co-localised
with Iba1-positive cells was detected (Figure 2A). For
mFPR2, a strong increase of immunoreactivity was evi-
dent in GFAP- as well as Iba-1-positive cells in the cor-
tex and hippocampus of APP/PS1 transgenic mice
(Figures 1B and 2B). For RAGE, the immunoreactivity
was strongest in the hippocampus in GFAP- and Iba1-
positive cells, but also in the cortex, an increase was
detected (Figures 1C and 2C). Please not that we did not
have observe a clear increase of receptor expession in
the near of the plaques.
To confirm the immunofluorescence studies, the mRNA
expression of mFPR1, mFPR2 and RAGE in the two brain
regions cortex and hippocampus was quantified using real-
time RT-PCR in APP/PS1 transgenic mice compared to
wildtype littermates. As shown in Figure 3A, the mFPR1
mRNA expression was significantly increased in the hip-
pocampus and cortex of the APP/PS1 transgenic mice
Figure 1 Increased formyl peptide receptors and RAGE expression in astrocytes in a APP/PS1 transgenic mouse model. Coronal brain
sections from twelve month old APPswe/PS1dE9 (APP/PS1) or wildtype (WT) mice were stained with anti-glial fibrillary acidic protein (GFAP) to
identify astrocytes (red) and anti-mFPR1 (A), anti-mFPR2 (B) or anti-RAGE (C) (green) antibodies (nuclear counterstaining in blue). The figures
show representative results for the cortex and hippocampus from one of three independent experiments (Scale bar = 200 μm for overview and
20 μm for detailed images).
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1,5 fold increase, p < 0.01 and p < 0.05; Figure 3A). For
mFPR2, the expression was significantly increased in the
cortex as well as the hippocampus (cortex: 9.8 ± 2.3
fold increase; hippocampus: 8.3 ± 1.7 fold increase,
both p < 0.01; Figure 3B). For RAGE, the maximum in-
duction of expression was detected in the hippocampus,
whereas in the cortex also a significant increase was
determined (cortex: 15.8 ± 3.5 fold increase; hippocam-
pus: 30.5 ± 10.6 fold increase, p < 0.01 and p < 0.05;
Figure 3C).Inhibition of RAGE-induced signal transduction by formyl
peptide receptor antagonist WRW4 in glial cells
We were able to detect an increased receptor expression
for formyl peptide receptors (mFPR1 and mFPR2) and
RAGE in the APPswe/PS1dE9 mice. In the next step we
investigated the glial cell activation by the different recep-
tor ligands. Therefore, we incubated primary rat astrocytes
and microglial cells with Aβ1–42 and fMLF as formylpep-
tide receptor agonists and S100B and AGE-BSA as RAGE
agonists to determine ERK1/2 phosphorylation and the
inhibition of forskolin-induced cAMP accumulation. The
Figure 2 Increased formyl peptide receptors and RAGE expression in microglial cells in a APP/PS1 transgenic mouse model. Coronal
brain sections from twelve month old APPswe/PS1dE9 (APP/PS1) or wildtype (WT) mice were stained with anti-ionized calcium binding adaptor
molecule-1 (anti-Iba-1) to identify microglial cells (red) and anti-mFPR1 (A), anti-mFPR2 (B) or anti-RAGE (C) (green) antibodies (nuclear
counterstaining in blue). The figures show representative results for the cortex and hippocampus from one of three independent experiments
(Scale bar = 200 μm for overview and 20 μm for detailed images).
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FPRL1 (homologous to mFPR2)[11]. As shown in Figure 4A
to D, treatment with Aβ1–42 and fMLF as well as S100B
and AGE-BSA resulted in an intense phosphorylation of
ERK1/2 in glial cells. The formyl peptide receptor antag-
onist WRW4 inhibited the Aβ1–42- and fMLF-induced
ERK1/2 phosphorylation in astrocytes as well as micro-
glia cells. This confirmed our previous results [11,13].
In addition, the present work showed that the S100B-
and AGE-BSA-induced ERK1/2 phosphorylation is also
inhibited by WRW4, which has no effect on ERK1/2phosphorylation by itself. In addition to the ERK1/2 phos-
phorylation mentioned, the formyl peptide receptors cap-
acity to inhibit cAMP formation was investigated. The
formyl peptide receptors are coupled to inhibitory G-
protein (Gi). The activation resulted in a reduction of
cAMP level. Forskolin was used as the activator of the
adenylate cyclase [12]. To determine whether the differ-
ent agonists inducing cAMP formation is linked via Gi
receptor activity, the cAMP production in glial cells was
induced by forskolin treatment, and the interference of
Aβ1–42, fMLF, S100B and AGE-BSA was analysed. As
Figure 3 Increased receptor expression in the cortex and hippocampus of twelve month old APP/PS1 transgenic mice. The cortex and
hippocampus from twelve month old APP/PS1 or wildtype mice were isolated and mRNA expression of mFPR1 (A), mFPR2 (B) or RAGE (C) were
determined using realtime RT-PCR. Data were assessed from six independent experiments in duplicate. An asterisk indicates a significant
difference (* = p < 0.05; ** = p < 0.01) compared to wildtype mice as determined by ANOVA followed by Bonferroni test.
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resulted in a strong increase of intracellular cAMP for
astrocytes (up to 56 ± 18 pmol/ml) and microglia (up to
38 ± 15 pmol/ml) as compared to untreated cells. The
change in the amount of cAMP was calculated as a per-
centage relative to forskolin. Application of both Aβ1–42
and fMLF counteracted the forskolin-induced cAMP for-
mation in glial cells and the decrease of cAMP level was
strongly inhibited by the formyl peptide receptors antag-
onist WRW4 [22]. This confirmed our previous results
[11,13]. In addition, also S100B as well as AGE-BSA
reduced forskolin-induced cAMP formation in astrocytes
and microglial cells (Figure 4E and F). Moreover, the
S100B- and AGE-BSA-induced decrease of cAMP level
was also blocked by the formyl peptide receptors antagon-
ist WRW4. These results suggest that FPR1/FPRL1 is
involved in RAGE signalling. WRW4 alone did not alter
the forskolin-stimulated adenylate cyclase activity in glial
cells.
Detection of the co-localization of RAGE and FPR1 as well
as FPRL1 in rat glial and transfected HEK293 cells by
immunofluorescence
As described above, S100B- and AGE-BSA-induced
ERK1/2 phosphorylation and the reduction of cAMP
levels were inhibited by the formyl peptide receptors an-
tagonist WRW4. One can assume that the effects of
RAGE are partly mediated by FPR1/FPRL1. To further
substantiate our findings, we examined the distribution
of FPR1, FPRL1 and RAGE in rat glial cells using double
fluorescencemicroscopy with receptor-specific antibodies.
For FPR1 and RAGE, both receptors are co-localised
mainly in the plasma membrane in astrocytes as well as
microglial cells (Figure 5A). Also FPRL1 showed over-
lapping staining with RAGE in the plasma membrane of
glial cells (Figure 5B). Next, we quantified the co-
localisation of fluorescent markers (see methods). The
right columns showed the results of a scatter plot of inten-
sities across the two channels (FPR1/FPRL1, green andRAGE, red). Coefficients of correlations are presented
over the scatter plots. The range is from −1, a strong
negative correlation, to +1, a strong positive correlation.
The closer to zero a coefficient is, the weaker the
correlation and hence the less evidence there is for co-
localisation. The Pearson correlation coefficient rp and
Spearman correlation coefficient rs are indicated on the
scatter plots. Between FPR1 and RAGE in astrocytes as
well as microglial cells, the coefficients illustrate a low
co-localisation. For FPRL1 and RAGE, the coefficients
confirm a good co-localization.
Furthermore, we analysed the FPR1/FPRL1 and RAGE
interaction in transfected HEK293 cells by fluorescence
microscopy. Therefore, we stably expressed human FPR1
or FPRL1 and RAGE or a RAGE mutant lacking the cy-
toplasmic and transducing domain (ΔRAGE) in HEK293
cells. As shown in Figure 6A and B, the FPR1 as well as
FPRL1 and RAGE are strongly co-localised in plasma
membrane. The co-localisation was also quantified and
the resulting scatter plot is showed in the right column.
The coefficients illustrate a good co-localisation between
FPR1 as well as FPRL1 and RAGE as well as ΔRAGE.
We were not able to detect a difference between RAGE
and ΔRAGE for co-localization.
RAGE interacts with FPR1 and FPRL1 in rat glial and
transfected HEK293 cells
To confirm our immunofluorescence results concerning
FPR1/FPRL1 and RAGE interaction, co-immunoprecipitation
studies were conducted using formyl peptide receptor
FPR1 or FPRL1 and RAGE antibodies. FPR1 or FPRL1
receptors were precipitated from lysates of rat glial cells
using anti-FPR1 or FPRL1 antibodies. The precipitates
were immunoblotted with antibodies directed against
FPR1, FPRL1 or RAGE. As shown in Figure 7A RAGE
was detected in immunoprecipitates from astrocytes and
microglial cells, suggesting that FPR1 or FPRL1 is phys-
ically associated with RAGE in vitro and/or under the
experimental conditions described. The band densities
Figure 4 Inhibition of RAGE-mediated G-protein receptor activity by the formyl peptide receptor antagonist WRW4 in glial cells. For
analysis of ERK1/2 phosphorylation, astrocytes (A) and microglia (B) were each treated with 1 μM Aβ1–42, 1 μM fMLF, 2.4 μM S100B or 0.75 μM
AGE-BSA (AGE) with or without 10 μM WRW4 and with WRW4 alone for 5 min at 37°C. Cells were lysed, equal amounts of protein (5 μg) were
dissolved in SDS sample buffer, and the levels of total ERK2 and phosphorylated phosphorylated ERK1/2 were determined via immunoblotting.
The positions of phospho-ERK1/2 (pERK1/2) and total ERK2 (ERK2) along with those of the molecular mass markers (in kDa) are indicated on the
left side. The values representing mean ± standard error of the mean (SEM) of phosphorylation levels derived from densitometric quantification of
three independent experiments are indicated in (C) and (D). An asterisk indicates a significant difference (* - p < 0.05) compared to control as
determined by one-way ANOVA and Bonferroni post-hoc test. In order to analyse the inhibition of forskolin-stimulated adenylate cyclase activity,
astrocytes (E) and microglia (F) were subjected to either 10 μM (E) or 25 μM (F) forskolin as well as well as to 1 μM Aβ1–42, 1 μM fMLF, 2.4 μM
S100B or 0.75 μM AGE-BSA (AGE) with or without 10 lM WRW4 and to WRW4 alone for 15 min at 37°C. cAMP levels were determined as
described above (see Methods). The values given represent mean ± SEM from four independent experiments. Asterisks indicate significant
differences (*, p < 0.05) between forskolin plus agonists and forskolin alone as determined by one-way ANOVA and Bonferroni post-hoc tests.
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quantification. As shown in Figure 7C, we did not detect
a difference between astrocytes and microglial cells for
RAGE in FPRL1 as well as FPR1 precipitates, but the
amount of co-immunoprecipitated RAGE was higher in
FPRL1 precipitates compared to FPR1 precipitates. To con-
firm the immunoprecipitation, we precipitate RAGE from
lysate of astrocytes or microglia. As shown in Figure 7A,
FPR1 and FPRL1 were detected in the immunprecipitates.
Furthermore, we analysed the FPR1/FPRL1 and RAGE
interaction in transfected HEK293 cells by co-immunopre-
cipitation. Co-immunoprecipitation studies were conductedwith anti-human FPR1 or FPRL1 antibodies using lysates
of FPR1/RAGE as well as FPR1/ΔRAGE or FPRL1-RAGE
as well as FPRL1/ΔRAGE expressing HEK293 cells. The
precipitates were immunoblotted with antibodies directed
against FPR1, FPRL1 or RAGE. As shown in Figure 7B,
RAGE was detected in immunoprecipitates from co-
transfected HEK293 cells, which confirms that FPR1 and
FPRL1 are physically associated with RAGE in vitro. The
mutant receptor ΔRAGE was also detected in the FPR1 as
well as FPRL1 precipitate. The densitometric quantifica-
tion of the band densities showed a significant decrease
of the amount of co-immunoprecipitated RAGE in the
Figure 5 FPR1 and FPRL1 are co-localised with RAGE in primary rat glial cells. Astrocytes and microglial cells were fixed and labelled with
anti-FPR1 (A) or anti-FPRL1 (B) and anti-RAGE antibodies. Localisation of FPR1, FPRL1 and RAGE was examined by double fluorescence
microscopy. Bisbenzimide was used for nuclear counter-staining (blue). The figures show representative results from one of three independent
experiments, each performed in duplicate. Scale bar: 20 μm. The right columns showed resulting scatter plot of intensities across the two
channels. The Pearson correlation coefficient rp and Spearman correlation coefficient rs are indicated on the scatter plots. For FPR1 (green
channel) and RAGE (red channel) (A), low co-localisation and for FPRL1 (green channel) and RAGE (red channel) (B) good co-localisation.
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HEK293 cells (Figure 7D).
Next, the protein receptor expression in the cell ly-
sates of glial and transfected HEK293 cells were deter-
mined. As shown in Figure 7E, FPR1, FPRL1 and RAGE
protein expression were detected in astrocytes, microglia
and the corresponding transfected HEK293 cells.
FPR1-, FPRL1- and RAGE-mediated ERK1/2
phosphorylation and change of cAMP levels in
transfected HEK293 cells
In an additional set of experiments, we investigated the ef-
fect of FPR1, FPRL1 and RAGE on Aβ1–42-, fMLF-,
S100B and AGE-BSA-induced signal transduction in
transfected HEK293 cells. For this purpose, we generated
FPR1-, FPRL1-, RAGE or ΔRAGE-expressing, and FPR1
or FPRL1 and RAGE or ΔRAGE-co-expressing HEK293
cells and analysed ERK1/2 phosphorylation after Aβ1–42-,fMLF-, S100B and AGE-BSA-treatment. The results of the
Western blots were quantified by densitometric quantifica-
tion. In un-transfected and ΔRAGE-expressing HEK293
cells, no stimulant resulted in an increase of the ERK1/2
phosphorylation (Figure 8A(a and b)). For RAGE-expressing
HEK293 cells, S100B as well as AGE-BSA induced an in-
crease of ERK1/2 phosphorylation in RAGE-expressing cells,
whereas Aβ1-42 and fMLF showed no effect (Figure 8A(c)).
In FPRL1-transfected and FPRL1-ΔRAGE-co-expressing
HEK293 cells, only Aβ1–42 and fMLF induced an increase
of ERK1/2 phosphorylation (Figure 8B(a and b)), whereas in
FPRL1-RAGE-co-expressing HEK293 cells, Aβ1–42, fMLF,
S100B and AGE-BSA significantly increased ERK1/2 phos-
phorylation (Figure 8B(c)). Interestingly, in FPR1-expressing
and FPR1-ΔRAGE-co-expressing HEK293 cells, Aβ1–42-
and fMLF- as well as S100B and AGE-BSA induced an in-
crease of ERK1/2 phosphorylation (Figure 8C(a and b)).
Furthermore, also in FPR1-RAGE-co-expressing HEK293
Figure 6 FPR1 and FPRL1 are co-localised with RAGE in transfected HEK293 cells. FPR1 (A) or FPRL1 (B) and RAGE or ΔRAGE transfected
HEK293 cells were fixed and labelled with anti-FPR1 (A) or anti-FPRL1 (B) and anti-RAGE antibodies. Localisation of FPR1, FPRL1 and RAGE/ΔRAGE
was examined by double fluorescence microscopy. Bisbenzimide was used for nuclear counter-staining (blue). The figures show representative
results from one of three independent experiments, each performed in duplicate. Scale bar: 20 μm. The right columns show the resulting scatter
plot of intensities across the two channels. The Pearson correlation coefficient rp and Spearman correlation coefficient rs are indicated on the
scatter plots. For FPR1/FPRL1 (green channel) and RAGE/ΔRAGE (red channel), please note a good co-localisation.
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nificantly ERK1/2 phosphorylation (Figure 8C(c)).
The above results are reflected in a change in forskolin-
induced adenylate cyclase activity. In hFPRL1-expressing
and FPRL1-ΔRAGE-co-expressing cells only the stimula-
tion with Aβ1–42 and fMLF were able to reduce the
cAMP level significantly (Figure 9A and C), whereas in
FPRL1-RAGE-co-expressing HEK293 cells also S100B and
AGE-BSA showed an effect on cAMP level (Figure 9B).
Interestingly, in FPR1-expressing HEK293 cells, Aβ1–42-
and fMLF- as well as AGE-BSA induced attenuated
forskolin-induced cAMP accumulation (Figure 9D).
S100B induced a slight but not significant reduction of
forskolin-induced adenylate cyclase activation. In FPR1-RAGE-co-expressing HEK293 cells Aβ1–42, fMLF, S100B
and AGE-BSA significantly reduced forskolin-induced
cAMP level. In contrast, co-expression with ΔRAGE can-
cels the effect of S100B and AGE-BSA compared to
Aβ1–42- as well as fMLF-mediated inhibition of forskolin-
induced cAMP accumulation (Figure 9E and F). In
HEK293 cells, only transfected with RAGE or ΔRAGE,
neither of the agonists induced a change of forskolin-
induced adenylate cyclase activation (Figure 9G and H).
Different receptors and S100B as well as Aβ1–42
co-localization in transfected HEK293 cells
After we were able to demonstrate an involvement of
the formyl peptide receptors in S100B- as well as AGE-
Figure 7 RAGE interacts with FPR1 and FPRL1 in glial and transfected HEK293 cells. (A) Membrane proteins from astrocytes or microglia
were extracted using anti-ratFPRL1 or ratFPR1 antibodies. (B) Membrane proteins from FPR1 or FPRL1 and RAGE or ΔRAGE transfected HEK293
cells were extracted and anti-humanFPRL1 or humanFPR1 antibodies were used to precipitate. The resulting immunoprecipitates were
electrophoretically separated, transferred to nitrocellulose and detected with anti-FPR1, anti-FPRL1 and anti-RAGE antibodies. FPR1 and FPRL1 are
co-immunoprecipitate with RAGE in glial as well as transfected HEK293 cells. The positions of molecular mass markers are indicated on the left (in
kDa). The values representing mean ± SD of protein and phosphorylation levels derive from densitometric quantification of three independent
experiments for co-immunoprecipitated RAGE (C for glial cells and D for transfected HEK293 cells) normalised to FPR1 or FPRL1. An asterisk
indicates a significant difference (*p < 0.05) compared to controls on the basis of one-way ANOVA and Bonferroni post-hoc tests. (E) Western
Blotting for different receptors of whole cell lysate from astrocytes, microglial and transfected HEK293 cells (each 10 μg protein). The positions of
molecular mass markers are indicated on the left (in kDa) and the target on the right.
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er a direct interaction between S100B or Aβ1–42 and
the receptors is detectable. Therefore, we analysed and
quantified the co-localisation of different receptors with
S100B as well as Aβ1-42 using fluorescence microscopy
after treatment of different receptor-expressing HEK293
cells with S100B or Aβ1–42 for 2 h. As shown in
Figure 10A, in untranfected HEK293 cells we did not de-
termine a detectable amount of bound S100B. In FPR1
expressing HEK293 cells, a slight increase of S100B in
the cells was detectable, whereas in FPRL1 expressing
HEK293 some S100B particles were identified. The lar-
gest amount of S100B was detected in RAGE expression
HEK293 cells. The co-localisation was also quantified
and the resulting scatter plot is in the right column. The
coefficients illustrate a low but existing co-localisation
between FPRL1 as well as RAGE and S100B. Between
FPR1 and S100B, the coefficients illustrate a poor co-
localisation.
For the Aβ1–42 and the different receptors, the co-
localisation was also quantified. The results in Figure 10Bshow a good co-localisation between Aβ1–42 and FPRL1,
whereas the coefficients illustrate a low but existing co-
localisation between FPR1 as well as RAGE and Aβ1–42.
Discussion
Our study shows the involvement of formyl peptide
receptors FPR1 and FPRL1 in Aβ1-42-induced signal
transduction in glial and transfected HEK293 cells. This
confirmed and extended our previous results for the
FPRL1 [11,13]. Interestingly, our results also show an in-
volvement of the high affinity receptor FPR1 in Aβ1-42-
induced signal transduction in transfected HEK293 cells.
A previous result from Le et al. [29] reported that Aβ1–
42 is able to activate FPR1 in transfected HEK293 and a
rat basophilic leukemia cell line, but that the receptor’s
efficacy in mediating cell migration and activation is much
lower than that of FPRL1. In our transfected HEK293
cells, we did not observe a clear difference between FPR1
and FPRL1 expressing cells in Aβ1-42-induced ERK1/2
phosphorylation or a change of cAMP accumulation
(Figures 8 and 9). Our previous results with small
Figure 8 FPR1-, FPRL1- and RAGE-mediated ERK1/2 phosphorylation in transfected HEK293 cells. For analysis of ERK1/2 phosphorylation,
(A) untransfected (a) or ΔRAGE (b), RAGE (c); (B) FPRL1 (a) and ΔRAGE (b) or RAGE (c); (C) FPR1 (a) and ΔRAGE (b) or RAGE (c) expressing HEK293
cells were treated with 1 μM Aβ1–42, 1 μM fMLF, 2.4 μM S100B or 0.75 μM AGE-BSA (AGE) for 5 min at 37°C. Cells were lysed, equal amounts of
protein (5 μg) were dissolved by SDS sample buffer, and levels of total ERK2 and phosphorylated ERK1/2 were determined by immunoblotting.
The positions of molecular mass markers are indicated on the right (in kDa). The mean ± SD of the three independent experiments were
evaluated by densitometric quantification normalised to ERK2 expression. Asterisks indicate a significant difference
(*, p < 0.05; **, p < 0,001) compared to control (one-way ANOVA followed by the Bonferroni test).
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Figure 9 FPR1-, FPRL1- and RAGE-mediated change of cAMP levels in transfected HEK293 cells. For analysis of inhibition of forskolin-
stimulated adenylate cyclase activity, FPRL1 (A) and RAGE (B) or ΔRAGE (C); FPR1 (D) and RAGE (E) or ΔRAGE (F); and RAGE (G) or ΔRAGE (H)
expressing HEK293 cells were subjected to 25 μM forskolin as well as 1 μM Aβ1–42, 1 μM fMLF, 2.4 μM S100B or 0.75 μM AGE-BSA (AGE) for
15 min at 37°C. cAMP levels were determined as described above (see Methods). The values represent mean ± SEM from four independent
experiments. Asterisks indicate a significant difference (*, p < 0.05; **, p < 0,01) between forskolin plus agonists and forskolin alone, as determined
by one-way ANOVA followed by the Bonferroni test.
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not result in an inhibition of Aβ1-42-induced ERK1/2
phosphorylation. However, the results could be explained
by the low FPR1 expression in the astrocytes as our pre-
vious results had shown [11]. It should be noted that
microglial cells show a higher endogen FPR1 expression.
In addition, other receptors are discussed for Aβ1-42-
induced glial cell activation. Other groups have reported
that the scavenger receptor MARCO (macrophage recep-
tor with collagenous structure), a cell surface glycopro-
tein, plays a role in the internalisation and Aβ1–42-
mediated microglia activation [16]. Our previous results
in astrocytes and transfected HEK293 cells did not show
an involvement of MARCO in Aβ1-42-induced ERK1/2
phosphorylation and change of cAMP accumulation [11].
Recent works suggested that scavenger receptors medi-
ate Aβ internalisation in microglial cells or activation
of perivascular macrophages [30,31]. A further receptor,
which is discussed in the context of the Aβ1-42-induced
glial cell activation, is RAGE. Previous studies had shown
that RAGE binds Aβ1–42 with high affinity in micro-
glial cells and neurons [17]. It was suggested thatRAGE-dependent signaling in microglial cells contri-
butes to neuroinflammation and Aβ accumulation as
well as impaired learning/memory in an APP/PS1 trans-
genic mouse model [32]. The crossing of these mice with
an inactive RAGE mutant resulted in a decrease of Aβ
levels and amyloid plaque load. It should be noted that
other working groups were not able to determine an
effect of RAGE in an APP/PS1 transgenic mouse model
[33]. However, our present results show a strong increase
of mice formyl peptide receptors mFPR1 and 2, the mice
homologon to human FPR1 and FPRL1, as well as RAGE
expression in the hippocampus and for mFPR2 also in
the cortex of the used APP/PS1 transgenic mice
(Figure 3). Nevertheless, it must be noted that nothing is
known about the increase of receptor expression in the
human AD brain. The increase was co-localised to astro-
cytes and microglia cells (Figures 1 and 2). Also for
MARCO, we were able to detect a strong increase of ex-
pression co-localised to glial cells (data not shown). This
extended previous results for RAGE and MARCO
[34,35]. Altogether, the increasing receptor expression
during the course of Aβ1-42 deposition in APP/PS1
Figure 10 (See legend on next page.)
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Figure 10 Different receptors and S100B or Aβ1–42 co-localisation in transfected HEK293 cells. Untransfected or FPR1-, FPRL1- or RAGE
expressing HEK293 cells were incubated with 2.4 μM S100B or 1 μM Aβ1–42 for 2 h. Cells were fixed and labelled with anti-FPR1, -FPRL1, -RAGE
and anti-S100B or anti- Aβ1–42 antibodies. Localisation of FPR1, FPRL1 or RAGE and S100B (A) or Aβ1–42 (B) was examined by double
fluorescence microscopy. Bisbenzimide was used for nuclear counter-staining (blue). The figures show representative results from one of three
independent experiments, each performed in duplicate. Scale bar: 20 μm. The right columns show the resulting scatter plot of intensities across
the two channels. The Pearson correlation coefficient rp and Spearman correlation coefficient rs are indicated on the scatter plots. For FPR1 (red
channel) and S100B or Aβ1–42 (green channel), poor or low co-localisation; for FPRL1 (red channel) and S100B or Aβ1–42 (green channel), low or
good co-localisation and for RAGE (red channel) and S100B or Aβ1–42 (green channel), both low co-localisation.
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tion including glial cell activation. The receptor activa-
tion of different signal transduction pathways including
NADPH oxidase or NFκB is increased. This may be asso-
ciated with an increased production of proinflammatory
cytokines and reactive oxygen species [36-38]. However,
a recent study showed that the mFPR2 acted as an anti-
inflammatory receptor [39]. It could also be a sign of the
increased uptake and clearance of Aβ. Our previous work
showed the involvement of FPRL1 in glial cells mediated
Aβ1-42 internalisation [13]. Possible, the increase of
receptor expression represents a protective function
against increased Aβ concentration in the brain. The
receptor-mediated internalisation could be an interesting
point to influence the plaque as well as AD development.
In this context, previous results showed that the glial
cells are able to internalise Aβ, although the uptake is de-
pendant on Aβ forms and size [13,40-42]. Further studies
must explore this topic.
Interestingly, in this study, we have demonstrated a phys-
ical interaction between FPR1 or FPRL1 and RAGE in glial
and transfected HEK293 cells by co-immunoprecipitation
and fluorescence microscopy for the first time (Figures 5
6 7). The densitometric quantification and quantitative
statistical co-localisation show that the interaction was
stronger between FPRL1 and RAGE compared to FPR1
and RAGE in glial cells. Differences between astrocytes,
microglial cells and in transfected HEK293 cells were de-
tectable. In FPR1 as well as FPRL1 and ΔRAGE, a RAGE
mutant lacking the cytoplasmic and transducing domain,
co-expressing HEK293 cells, showed that the interaction
was significantly but not completely reduced (Figure 7).
The intracellular domain is possibly involved in the
binding between FPR1/FPRL1 and RAGE. The function
of this interaction remains unclear. However, our previ-
ous results showed a physical and functional interaction
between FPR1/FPRL1 and MARCO [11]. The findings
suggest that the receptors interaction influences the re-
ceptor activity by cross-phosphorylation and desensitisa-
tion of downstream signalling pathways. Such influence
was also detected for other receptor classes. For exam-
ple, studies have shown an extensive cross-talk between
opioid- and somatostatin-receptors mediated analgesicresponses and pain-processing pathways [43,44]. For the
interaction between FPR1/FPRL1 and MARCO as well
as RAGE, it is possible that the pattern recognition re-
ceptors complement, modulate and enhance each other
of their effects. By this, they could enhance the response
of the innate immune system or even the inflammatory
response in Alzheimer's disease.
For the signal transduction pathways, our results for
ERK1/2 phosphorylation and the change of cAMP accu-
mulation show that the specific formyl peptide receptors
antagonist WRW4 inhibited RAGE ligands S100B- as
well as AGE-BSA-induced glial cell activation (Figure 4).
Furthermore, the findings confirmed the importance of
the FPRL1 in Aβ1–42-induced signal transduction. How-
ever, the results with transfected HEK293 cells showed
that S100B- or AGE-BSA-induced ERK1/2 phosphoryl-
ation and inhibition of cAMP level is not mediated by
FPRL1, whereas FPR1 is involved (Figures 8 and 9). In-
terestingly, FPR1 expressing HEK293 cells also mediate
an Aβ1–42-induced ERK1/2 phosphorylation and a
change of cAMP accumulation, whereas our results did
not confirm an involvement of RAGE. In addition, a co-
transfection of RAGE in FPR1 or FPRL1 expressing cells
resulted in an amplification of the S100B- as well as
AGE-BSA-induced signal transduction. For the involve-
ment of the receptors in S100B or Aβ1–42-induced signal-
ling, the immunofluorescence and quantitative statistical
co-localisation confirmed that RAGE but also FPR1 bind-
ing S100B, whereas the co-localisation of Aβ1–42 and
FPRL1 is strongest (Figure 10). Altogether, the findings
suggest complementary and synergic action between the
receptors. The elucidation of consequences for receptor
activities and inflammation as well as the progression of
the AD need further investigations. Nevertheless, previ-
ous kinetics studies showed a binding of Aβ and RAGE
in endothelial cells and cortical neurons [45]. I can be
assumed that the binding depends on the Aβ forms
(monomeric, oligomeric or fibrillary). For the present
study, we used non-fibrillary Aβ1-42. In addition, it must
be noted that in the primary cells, the mediation of the
effect by other receptors cannot be excluded. Further-
more, it was shown that microglial cells behave differ-
ently depending upon age in interaction with fibrillary
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should bring more clarity here.
In conclusion, there is a substantial interest to identify
the cell surface receptors that bind and mediate the intra-
cellular effects of Aβ1-42 in glial cells. Consequently, FPR1/
FPRL1 and RAGE or MARCO interactions may explain
how formyl peptide receptors interact with a menagerie of
structurally diverse pro- and anti-inflammatory ligands
associated with different diseases including amyloidosis,
Alzheimer’s disease, prion disease and HIV, or with bacter-
ial components [14,21]. Interactions with other receptors
may support and modulate the cellular reaction to such
structurally diverse ligands by the formyl peptide receptors.
Altogether, we hypothesise that formyl peptide receptors
play a central role in neurodegenerative mechanisms and
physiological regulatory processes.
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